It takes two.

Unfortunately, nivolumab hasn’t proven to do much for recurrent or refractory ovarian cancer. This NRG phase 2 trial aimed to assess whether that classic combo nivo + ipilimumab could do the trick. 100 women with epithelial ovarian cancer failing at least one prior line of systemic therapy were randomized to nivo monotherapy versus nivo + ipi x 4 then maintenance nivo monotherapy. The primary endpoint of objective response rate at 6 months was improved from 12 → 31% with combo therapy (OR 3.3). What’s more, median progression-free survival was doubled—albeit that was an easy target—from 2 → 4 months. Importantly, this was all regardless of PD-L1 expression. TBL: Further manipulation of immune responses to ovarian cancer are probably worth pursuing. | Zamarin, J Clin Oncol 2020